Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine
- PMID: 7526567
- DOI: 10.1016/0264-410x(94)90029-9
Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine
Abstract
A Salmonella typhi conjugated vaccine was prepared by covalently linking the antigenic O-polysaccharide, selectively activated by periodate oxidation, to tetanus toxoid via reductive amination. The immunogenicity of the conjugate (O-TT) was examined by injecting Balb/c mice with 5 micrograms of the conjugate and Alhydrogel as adjuvant, boosting 14 and 28 days after the primary immunization, and quantification of the development of anti-polysaccharide and anti-tetanus toxoid antibodies by enzyme-linked immunosorbent assay. Mean anti-O-chain titres after the first and second boost were 129 and 502, respectively, while anti-tetanus toxoid titres were 159 and 1000, respectively. Anti-O-polysaccharide antibodies exhibited complement-mediated bactericidal activity against S. typhi. Immunized mice were fully protected against challenge with 10 LD50 of S. typhi Ty2 (p < 0.001) and partially protected against challenge with 100 LD50 of S. typhi Ty2 (p < 0.04).
Similar articles
-
Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model.Can J Microbiol. 2005 Apr;51(4):319-24. doi: 10.1139/w05-008. Can J Microbiol. 2005. PMID: 15980894
-
Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.Vaccine. 2007 Nov 14;25(46):7972-80. doi: 10.1016/j.vaccine.2007.06.018. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17936445
-
Salmonella typhi O:9,12 polysaccharide-protein conjugates: characterization and immunoreactivity with pooled and individual normal human sera, sera from patients with paratyphoid A and B and typhoid fever, and animal sera.J Clin Microbiol. 1993 Apr;31(4):975-8. doi: 10.1128/jcm.31.4.975-978.1993. J Clin Microbiol. 1993. PMID: 7681853 Free PMC article.
-
Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.Vaccine. 2017 Jun 5;35(25):3286-3294. doi: 10.1016/j.vaccine.2017.04.078. Epub 2017 May 6. Vaccine. 2017. PMID: 28487056 Review.
-
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.J Infect Dis. 1984 Sep;150(3):436-49. doi: 10.1093/infdis/150.3.436. J Infect Dis. 1984. PMID: 6207249 Review.
Cited by
-
A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidal Salmonella serovars.Front Immunol. 2024 Jan 9;14:1304170. doi: 10.3389/fimmu.2023.1304170. eCollection 2023. Front Immunol. 2024. PMID: 38264668 Free PMC article.
-
Salmonella enterica serovar Typhi O:1,9,12 polysaccharide-protein conjugate as a diagnostic tool for typhoid fever.J Clin Microbiol. 2005 Sep;43(9):4545-50. doi: 10.1128/JCM.43.9.4545-4550.2005. J Clin Microbiol. 2005. PMID: 16145105 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources